Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasal Abuse Potential of PTI-821
NCT03475862Phase 1Completed
- Sponsor
- Cassava Sciences
- Start
- May 2017
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of oxycodone in chronic pain (5 arms), sponsored by Cassava Sciences. Primary endpoint: Drug Liking Emax. Started May 2017; status: completed.
02
Drugs
oxycodone
03
Conditions
chronic pain
Beyond the preview
Go deeper on NCT03475862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03475862.